PDE4B and B-cell non-Hodgkin lymphoma: Meanwhile, miR-124 also increases sensitivity of B-cell lymphomas to glucocorticoid treatment by targeting phosphodiesterase 4B (PDE4B) and may act as an attractive therapeutic target in B cell lymphoma (48).